A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting
Sánchez‐Rovira, Pedro, Hirschberg, Angelica Lindén, Gil‐Gil, Miguel, Bermejo‐De Las Heras, Begoña, Nieto‐Magro, Concepción
Published in The oncologist (Dayton, Ohio) (01.12.2020)
Published in The oncologist (Dayton, Ohio) (01.12.2020)
Get full text
Journal Article
Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
Quintela-Fandino, M., Manso Sànchez, L.M., Holgado Martín, E., Moreno, M.C., Morales Murillo, S., Bermejo De Las Heras, B., Malon Gimenez, D., Colomer Bosch, R., Gonzalez Cortijo, L., Hornedo, J., Mouron, S., Muñoz, M., Escudero, S., Blanco, R., Mañes, S.
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
Selective sentinel node biopsy after intratumour administration of radiotracer in breast cancer patients treated with neoadjuvant chemotherapy in relation to the level of tumour response
Díaz-Expósito, R, Martí-Bonmatí, L, Burgués, O, Casáns-Tormo, I, Bermejo-de Las Heras, B, Julve-Parreño, A, Caballero-Garate, A
Published in Revista espanola de medicina nuclear e imagen molecular (01.11.2016)
Published in Revista espanola de medicina nuclear e imagen molecular (01.11.2016)
Get more information
Journal Article
Selective sentinel node biopsy after intratumour administration of radiotracer in breast cancer patients treated with neoadjuvant chemotherapy in relation to the level of tumor response
Díaz-Expósito, R, Martí-Bonmatí, L, Burgués, O, Casáns-Tormo, I, Bermejo-de las Heras, B, Julve-Parreño, A, Caballero-Garate, A
Published in Revista Española de medicina nuclear e imagen molecular (English ed.) (01.11.2016)
Published in Revista Española de medicina nuclear e imagen molecular (English ed.) (01.11.2016)
Get full text
Journal Article
93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
Gebhart, G., Keyaerts, M., Guiot, T., Flamen, P., Ruiz Borrego, M., Stradella, A., Bermejo De Las Heras, B., Escriva de Romani, S., Calvo-Martinez, L., Ribelles Entrena, N., Martinez, N., Albacar Miro, C.R., Colleoni, M.A., Atienza de Frutos, M., Sampayo-Cordero, M., Cortés, J., Perez Garcia, J.M., Llombart Cussac, A.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials
Martin Jimenez, M., Rodríguez-Lescure, A., Andres Conejero, R., Servitja Tormo, S., Anton Torres, A., Ruiz Borrego, M., Bermejo De Las Heras, B., Guerrero, A., Ramos Vazquez, M., Santaballa Bertran, A., Munoz, M., Batista, J.N., Lopez-Tarruella Cobo, S., Chacon Lopez-Muniz, J.I., Alvarez Lopez, I., Martinez del Prado, M.P., Miralles, J.J., Polonio, O., Jara Sanchez, C., Mori de Santiago, M.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study
Pascual, T., Bermejo De Las Heras, B., Martinez, N., Oliveira, M., Pernas Simon, S., Lopez Lopez, R., Ruiz Cabrero, I., Alarcon, J.D., Martinez De Dueñas, E., Malon Gimenez, D., Gonzalez Cao, M., Manso Sanchez, L.M., Morales Murillo, S., Lopez de Ceballos, H., Cortés, J., Llombart Cussac, A., Prat, A.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
Teng, N., Dalby, M.J., Kiu, R., Robinson, T., Gion Cortes, M., Bermejo De Las Heras, B., Perez Garcia, J.M., Calvo-Martinez, L., Prat, A., Marquez Vazquez, R., Ruiz Borrego, M., de la Cruz, S., Llombart Cussac, A., Curigliano, G., Schmid, P., Mancino, M., Hall, L., Robinson, S., Cortés, J., Malfettone, A.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy
Martinez Saez, O., Hernando Melia, C., Rey, M., Chic, N., Martinez, M.T.M., Cebrecos, I., Bermejo De Las Heras, B., Bargalló, X., Burgués, O., Ganau, S., Úbeda, B., Mollá, M., Vidal-Siscart, S., Sanfeliu Torres, E., Gonzalez-Farre, B., Vidal, M., Adamo, B., Munoz, M., Prat, A., Cejalvo Andujar, J.M.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial
Ciruelos, E.M., Ponce, J., Pernas Simon, S., Cortés, J., Cantos, B., Garate, E., Vega Alonso, E., Mele Olive, M., Martinez De Dueñas, E., Montaño Perianez, A., Martinez, N., Perello Martorell, A., Bermejo De Las Heras, B., Arqueros Nunez, C., Fernández, I., De la Haba Rodriguez, J., Oliveira, M., González, X., Villagrasa Gonzalez, P., Prat, A.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
354TiP Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study
Todo, F. Rojo, Stradella, A., García-Sáenz, J.A., De Las Heras, B. Bermejo, Romero, J.L. Alfonso, Barnadas, A., Peron, Y. Izarzugaza, Alba, E., López-Tarruella, S., Henao-Carrasco, F., Carrasco, E., Caballero, R., Del Campo, M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial
Llombart Cussac, A., Prat, A., Pérez-García, J.M., Mateos, J., Pascual, T., Escrivà-De-Romani, S., Stradella, A., Ruiz-Borrego, M., Bermejo De Las Heras, B., Keyaerts, M., Sampayo-Cordero, M., Malfettone, A., Cortés, R., Galván, P., Cortés, J., Gebhart, G.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
129TiP Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR)[+]/HER2[–] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
Llombart Cussac, A., Pérez-Garcia, J.M., Blanch, S., Tolosa, P., Ruiz Borrego, M., Gion Cortes, M., Fernádez, A., Urruticoechea, A., Galve, E., Cueva Banuelos, J.F., Ponce, J., Alonso, J.L., Capelán, M., Martínez, E., Bermejo De Las Heras, B., Rojas, B., Martos, T., López, A., Gómez-Peralta, F., Cortés, J.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
Ciruelos, E.M., Garcia, A.A., Cortés, J., Pernas Simon, S., Garate, E., Melé, M., Montaño, Á., Martinez-Jañez, N., Oliveira, M., Haba-Rodríguez, J. de la, Vega, E., Martorell, A. Perello, Bermejo De Las Heras, B., Cantos Sanchez De Ibarguen, B., Martínez, E., Navarro, E. Vila, Pascual, T., González-Farré, X., Villagrasa, P., Prat, A.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
319P Prognosis for patients with oligometastatic breast cancer who achieve NED status after systemic and local therapy
Aguado, E. Olcina, Martinez, M.T.M., Carbonell-Asins, J.A., Montón-Bueno, J., Ortega, B., Poveda, J., Tapia, M., Moragón, S., Melia, C. Hernando, Candia, L., Simon, S., Adam-Artigues, A., Garrido-Cano, I., Pattanayak, B., Tormo, E., Eroles, P., Lluch, A., De Las Heras, B. Bermejo, Cejalvo, J.M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Abstract OT3-02-05: CORALLEEN: A phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment for postmenopausal patients with luminal B/HER2-negative breast cancer
Gavila, J, Saura, C, Oliveira, M, Ciruelos, E, Gonzalez, X, de la Peña, L, Bermejo de las Heras, B, Muñoz, M, Fernandez, P, Villagrasa, P, Ortega, V, Lopez, R, Celiz, P, Pascual, T, Prat, A
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial
Ciruelos, E.M., Villagrasa, P., Oliveira, M., Pernas Simon, S., Cortés, J., Vazquez, S., Martínez, N., Perelló, A., Bermejo De Las Heras, B., Martínez, E., Garau Llinas, I., Mele Olive, M., Montaño, A., Vega, E., Cantos, B., Echarri, M.J., Pascual, T., Celiz, P., González-Farré, X., Prat, A.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
Kahan, Z., Gil-Gil, M., Ruiz-Borrego, M., Carrasco, E.M., Ciruelos, E.M., Muñoz, M., Bermejo De Las Heras, B., Margeli Vila, M., Anton, A., Casas, M., Calvo, L., de la Haba, J., Ramos, M., Álvarez-López, I., Gal-Yam, E., Gautier, E., Corsaro, M., Rodrigálvarez, G., Zielinski, C., Martin Jimenez, M.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
Abstract P3-12-01: 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”
Sánchez-Rovira, P, Hirschberg, AL, Gil-Gil, M, Antolín-Novoa, S, García-Estévez, L, Bermejo de las Heras, B, Presa-Lorite, J, Sánchez-Vigil de la Villa, I, Suárez-Almarza, J, Nieto-Magro, C
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article